A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis

A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis

This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.

Detalles Bibliográficos
Autor principal: Islam, Nahidul
Otros Autores: Talukder, Mesbah
Formato: Tesis
Lenguaje:English
Publicado: Brac University 2023
Materias:
Psoriasis
Biologics
FAERS
Interleukin inhibitors
Alopecia
Pharmacovigilance
Acceso en línea:http://hdl.handle.net/10361/22025
id 10361-22025
record_format dspace
spelling 10361-220252024-01-02T06:39:39Z A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis Islam, Nahidul Talukder, Mesbah School of Pharmacy, Brac University Psoriasis Biologics FAERS Interleukin inhibitors Alopecia Pharmacovigilance This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. Cataloged from PDF version of thesis. Includes bibliographical references (pages 20-24). FDA has approved about 12 biologics for treating psoriasis. Among them, TNF-α inhibitors have a history of causing alopecia while used for treatment. In our study, we tried to find out the relation between alopecia and the FDA-approved biologics that are interleukin inhibitors while treating psoriasis. In our study, we include data from FDA Adverse Event Reporting System (FAERS) to find out Reporting Odds Ratio and Confidence Interval (CI). For interleukin inhibitors Ustekinumab, Guselkumab, Brodalumab, Ixekizumab and Secukinumab, the lower bound of CI were less than 1. We did not find any value for Tildrakizumab and Risankizumab. We did not find any signal for adverse event Alopecia. There are several cases available that says that, IL-17A causes alopecia when given to patients. More investigation is required to find out connection between them for the safety and find better alteration of these drugs if needed. Nahidul Islam B. Pharmacy 2023-12-21T06:59:06Z 2023-12-21T06:59:06Z 2023 2023-02 Thesis ID 19146034 http://hdl.handle.net/10361/22025 en Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 24 pages application/pdf Brac University
institution Brac University
collection Institutional Repository
language English
topic Psoriasis
Biologics
FAERS
Interleukin inhibitors
Alopecia
Pharmacovigilance
spellingShingle Psoriasis
Biologics
FAERS
Interleukin inhibitors
Alopecia
Pharmacovigilance
Islam, Nahidul
A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
description This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
author2 Talukder, Mesbah
author_facet Talukder, Mesbah
Islam, Nahidul
format Thesis
author Islam, Nahidul
author_sort Islam, Nahidul
title A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
title_short A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
title_full A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
title_fullStr A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
title_full_unstemmed A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
title_sort pharmacovigilance study on fda approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
publisher Brac University
publishDate 2023
url http://hdl.handle.net/10361/22025
work_keys_str_mv AT islamnahidul apharmacovigilancestudyonfdaapprovedinterleukininhibitorassociatedalopeciainthetreatmentofpsoriasis
AT islamnahidul pharmacovigilancestudyonfdaapprovedinterleukininhibitorassociatedalopeciainthetreatmentofpsoriasis
_version_ 1814309072009166848

Ejemplares similares